The benefit ratio for our Unum US segment was 60.8 percent in the first quarter of 2023, compared to 72.5 percent in first quarter of 2022.Unum US sales increased 22.5 percent in first quarter 2023 compared to the same period of 2022.The long-term care interest adjusted loss ratio was less favorable during the first quarter of 2023 relative to the same period of 2022 but is within our long-term range of expectations.The amortization of deferred acquisition costs in the first quarter of 2023 was generally consistent compared to the same period of 2022.Net investment income was lower in the first quarter of 2023 relative to the same period of 2022 due to lower investment income from inflation index-linked bonds.The average new case size decreased 7.9 percent in the first quarter of 2023 compared to the same period of 2022.Premium income for long-term care in the first quarter of 2023 was generally consistent with the same period of 2022.The interest adjusted loss ratio for long-term care was less favorable during the first quarter of 2023 relative to the same period of 2022 driven primarily by higher claim incidence.The decrease in the effects of non-contemporaneous reinsurance treatment in the first quarter of 2023 compared to the first quarter of 2022 is due to less favorable experience in this block in the first quarter of 2023 which resulted in a smaller net change in reserves in the first quarter of 2023 as compared to the first quarter of 2022.We recorded net investment income totaling $14.3 million for the partnerships in the first quarter of 2023 reflecting the market conditions of the fourth quarter of 2022.Commissions and the deferral of acquisition costs were higher during the first quarter of 2023 compared to the same period of 2022 driven by higher sales and in-force block growth in our principal operating business segments.The increase in amortization of deferred acquisition costs in the first quarter of 2023 compared to the same period of 2022 is due primarily to growth in the level of the deferred asset in our Unum US voluntary benefits product line and in our Colonial Life segment.Other expenses and compensation expense, on a combined basis, increased in the first quarter of 2023 compared to the same period of 2022 due to an increase in employee-related expenses, an increase in operational investments in our business, and growth in our fee-based service products.Sales shown in the preceding chart generally represent the annualized premium income on new sales which we expect to receive and report as premium income during the next 12 months following or beginning in the initial quarter in which the sale is reported, depending on the effective date of the new sale.Other income increased in the first quarter of 2023 compared to the same period of 2022 due to growth in our fee-based service products.The benefit ratio was favorable in the first quarter of 2023 compared to the same period of 2022 due to lower claims incidence in both the group short-term and long-term disability product lines, favorable claim resolutions driven by recoveries in our group long-term disability product line, and favorable discount rate impacts on new claims.As a result, the increase in the discount rates for the first quarter of 2023 compared to the same period of 2022 contributed to the favorable benefits experience.104 Commissions and the deferral of acquisition costs were higher in the first quarter of 2023 compared to the same period of 2022 due primarily to in-force block growth and higher sales.The amortization of deferred acquisition costs increased in the first quarter of 2023 compared to the same period of 2022 primarily due to an increase in lapses in our group short-term disability product line.105 Commissions and deferral of acquisition costs were higher in the first quarter of 2023 compared to the same period of 2022 due to higher sales.The other expense ratio increased in the first quarter of 2023 compared to the same period of 2022 due primarily to an increase in employee-related costs and operational investments in our business.The benefit ratio for individual disability was favorable in the first quarter of 2023 compared to the same period of 2022 due primarily to higher mortality and lower claims incidence.The benefit ratio for dental and vision was unfavorable in the first quarter of 2023 compared to the same period of 2022 due primarily to higher claims incidence.Commissions and deferral of acquisition costs were higher for the first quarter of 2023 relative to the same period of 2022 due primarily to higher sales in the voluntary benefits and individual disability product lines.The amortization of deferred acquisition costs increased in the first quarter of 2023 relative to the same period of 2022 due to growth in the level of the deferred asset.Our other expense ratio increased in the first quarter of 2023 compared to the same period of 2022 due primarily to an increase in employee-related costs and an increase in operational investments in our business.SalesGroup sales increased during the first quarter of 2023 compared to the same period of 2022 due to growth with existing customers in both the core market, which we define as employee groups with fewer than 2,000 employees, and the large case market, partially offset by lower sales to new customers in both the core and large case markets.Voluntary benefits sales increased during the first quarter of 2023 compared to the same period of 2022 due primarily to higher sales to new customers in the large case markets.Individual disability sales, which are primarily concentrated in the multi-life market, increased in the first quarter of 2023 compared to the same period of 2022 due to higher sales to both new and existing customers.Dental and vision sales were generally consistent in the first quarter of 2023 compared to the same period of 2022 with lower sales to new customers offset by higher sales to existing customers.Premium income was higher in the first quarter of 2023 compared to the same period of 2022 due to in-force block growth and higher sales.The other expense ratio was higher in the first quarter of 2023 relative to the same prior year period due to an increase in operational investments in the business.Group long-term disability sales decreased in the first quarter of 2023 compared to the same period of 2022, driven by lower sales to new and existing customers in the large case market, which we define as employee groups with greater than 500 employees, partially offset by higher sales to new and existing customers in the core market.Group life sales increased in the first quarter of 2023 compared to the same period of 2022 driven by higher sales to new and existing customers in both the core and large case markets.111 Supplemental sales increased in the first quarter of 2023 compared to the same period of 2022 due to higher sales in our group critical illness and dental product lines.113 Commissions and the deferral of acquisition costs were higher in the first quarter of 2023 relative to the same period of 2022 due to higher sales in prior periods.The amortization of deferred acquisition costs in the first quarter of 2023 was higher relative to the same period of 2022 due to growth in the level of the deferred asset.The other expense ratio was higher in the first quarter of 2023 relative to the same period of 2022 due primarily to an increase in employee-related costs and an increase in operational investments in our business.SalesCommercial market sales decreased during the first quarter of 2023 compared to the same period of 2022 due to lower sales to existing customers in the large case market and to new customers in the core market, which we define as accounts with fewer than 1,000 employees.Public sector market sales increased in the first quarter of 2023 compared to the same period of 2022 due to higher sales to existing customers, partially offset by lower sales to new customers.The other expense ratio, excluding the amortization of the cost of reinsurance related to the Closed Block individual disability reinsurance transaction, was higher in the first quarter of 2023 relative to the same period of 2022 due primarily to a decline in the expense allowance related to the ceded block of individual disability business and an increase in employee-related costs.